Tango Therapeutics Announces Presentation of TNG908 Preclinical Combination Data at 2022 ESMO Targeted Anticancer Therapies Congress
March 03, 2022 09:41 ET
|
Tango Therapeutics, Inc.
CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...
Tango Therapeutics to Participate in Upcoming Investor Conferences
February 28, 2022 07:00 ET
|
Tango Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...
Tango Therapeutics to Participate in Upcoming Investor Conferences
February 02, 2022 07:00 ET
|
Tango Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...
Tango Therapeutics Announces Clearance of TNG908 IND by FDA and Recent Pipeline Progress Updates
January 24, 2022 07:00 ET
|
Tango Therapeutics, Inc.
- TNG908 IND cleared by FDA, Phase 1/2 trial expected to start in 1H 2022 - Additional pipeline programs progressing throughout 2022 CAMBRIDGE, Mass., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Tango...
Tango Therapeutics to Participate in the Jefferies London Healthcare Conference
November 11, 2021 07:00 ET
|
Tango Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...
Tango Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights
November 09, 2021 07:00 ET
|
Tango Therapeutics, Inc.
- Strong cash position of $504 million supports advancing discovery and clinical pipeline into second half of 2024 - - On track for IND filing in fourth quarter of 2021 for TNG908, an...
Tango Therapeutics Announces Appointment of Dr. Marc Rudoltz as Chief Medical Officer and Doug Barry as General Counsel
November 01, 2021 07:00 ET
|
Tango Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...
Tango Therapeutics Debuts as Publicly Traded Precision Oncology Company Focused on the Next Generation of Targeted Cancer Therapies
August 10, 2021 09:00 ET
|
Tango Therapeutics, Inc.
– Business combination transaction with BCTG Acquisition Corp., a special purpose acquisition company sponsored by Boxer Capital, completed today – – Combined company Tango Therapeutics, Inc. will...